Multiple layers of suppressive components including regulatory T (T Reg ) cells, suppressive antigen-presenting cells, and inhibitory cytokines form suppressive networks in the ovarian cancer microenvironment. It has been demonstrated that as a major suppressive element, T Reg cells infiltrate tumor, interact with several types of immune cells, and mediate immune suppression through different molecular and cellular mechanisms. In this paper, we focus on human ovarian cancer and will discuss the nature of T Reg cells including their subsets, trafficking, expansion, and function. We will briefly review the development of manipulation of T Reg cells in preclinical and clinical settings.
Introduction
Ovarian cancer is one of the most common and deadliest gynecologic cancers. In 2010, 21880 new cases were diagnosed, and such cancer caused nearly 13850 deaths in the United States alone [1] . Ovarian cancer usually has poor prognosis, and most patients were diagnosed at advanced stages. The five-year survival rate for all stages of ovarian cancer is 46% in 2010 [1] . It has been well documented that patients' clinical outcome and five-year survival rate are positively associated with the number of tumor-infiltrating lymphocytes (TILs) [2] , and the ratio of intraepithelial CD8 + TILs to T Reg cells [3] , or negatively associated with tumor-infiltrating T Reg cells [4] .
T Reg cells are also known as suppressor T cells which consist of a specific subpopulation of cells that functionally suppress the activation of immune system and maintain immune tolerance to self-antigens. T Reg cells contain two major subsets known as natural T Reg cells (nT Reg Because most tumors express self-antigens, T Reg cells-mediated immunosuppression is believed to be one of the major contributors to immune evasion by tumors and becomes the main obstacle toward successful tumor immunotherapy [6] . In this paper, we will focus on human ovarian cancer and discuss the nature of T Reg cells including their subsets, trafficking, differentiation, and proliferation and the clinical application of manipulation of T Reg cells.
Regulatory T-Cell Subsets
In early 1970s, Gershon and Kondo first described the existence of thymus-derived suppressive T cells (later termed as T Reg cell) in vivo [7, 8] . After more than a decade, Sakaguchi et al. demonstrated that CD4 + T cells expressing interleukin-2 (IL-2) receptor alpha-chain (CD25) can be defined as the population of T Reg cells with immune-suppressive activities and maintaining immune tolerance to self-antigen [ 
Regulatory T-Cell Trafficking
T Reg cells consist of ∼10% of peripheral CD4 + T cells characterized as CD4 + CD25 + FOXP3 + T cells, which is important for the control of autoimmune reaction [9, 11] . Dysregulation of T Reg can cause autoimmune diseases [17] and may contribute to tumor-initiated immune evasion [18] . As demonstrated by in vivo mouse model, the deletion of T Reg cells results in tumor rejection [19] . However, the suppressive capacity of T Reg cells is also determined by the ratio of T Reg cells to effector T cells [3] . A high CD8 + /T Reg ratio is associated with favorable prognosis and improved survival [3, 20] . It has been reported that many human cancers are associated with high frequency of T Reg cells in the circulation or in the tumor tissues, including ovarian cancer [ [27] . Chemokine CCL22, the ligand for CCR4, preferentially attracts activated-antigen-specific T cells to dendritic cells [28, 29] . It has also been shown that human ovarian cancer cells and tumor-associated microphages produce chemokine CCL22, which mediates T Reg cells trafficking to tumor [4] . Blockade of CCL22 in vivo significantly reduces human T Reg cells trafficking to tumors in ovarian carcinoma [4] . This chemokine-mediated T Reg trafficking has been also observed in other types of cancer, such as gastric cancer [30] , Hodgkin's lymphoma [31] , and breast cancer [32] . Interestingly, in gastric cancer, CCL22 and CCL17 seem both important to recruit T Reg cells to the tumors as demonstrated by in vivo study as well as in vitro migration assay, and the levels of CCL22 and CCL17 within tumors are correlated to the increased levels of T Reg cells in early gastric cancer [33] .
Besides CCR4 chemokine axis, CCR5/CCL5 axis may also selectively recruit T Reg cells to the tumors. Using human pancreatic adenocarcinoma and murine pancreatic tumor model, it has been found that CCR5 is highly expressed in T Reg cells, while tumor cells produce elevated amount of CCL5, and disruption of CCR5/CCL5 chemokine axis blocks T Reg cells migration and reduces tumor growth [34] .
In addition, CCL20 chemokine shows high affinity to CCR6 and can also mediate selective CCR6 + T Reg cells trafficking [35] .
Regulatory T-Cell Differentiation and Proliferation
CD4 + CD25 + T Reg cells are generated in the thymus. Papiernik et al. found that peripheral T Reg migrates from the thymus and appears in the periphery as early as 10th day of life [36] . They also found that CD4 + CD25 + T Reg cells differentiation is totally dependent on IL-2, because IL-2 knockout mice do not develop CD4 + CD25 + T Reg in vivo [36] . Further evidences have been provided from the studies on irradiated rat model [37] . In this study, autoimmune diseases were induced in rats by thymectomy and irradiation; however the xenograft transfer of CD4 + T cells from normal rats can abrogate the autoimmune responses. These observations suggest that normal thymus-derived T cells have immune suppressive functions and thus prevent autoimmunity [37] . In another model system, adoptive transfer of thymocytes or peripheral T cells depleted of CD4 + CD25 + T Reg cells causes autoimmune diseases in mice, which provides further evidences of thymic origin of T Reg cells and their peripheral existence [38] . However, there is little known about the comprehensive requirements for thymic T Reg development. Although there are several arguments about how and what stromal components are involved in thymic T Reg cell differentiation, thymic stromal cells, including cortical and medullary thymic epithelial cells and dendritic cells (DCs), contribute to T Reg cells differentiation and selection [38] . Jordan et al. used TCRtransgenic mice which express the receptor recognizing specific self-antigen and found that thymocytes bearing a TCR with high affinity to a specific self-antigen undergo selection and become CD4 + CD25 + T Reg cells when interacting with a single self-antigen, but thymocytes bearing TCR with low affinity do not undergo selection [39] .
In addition to thymus, T Reg can also be generated in the periphery. For instance, tumor microenvironment favors the induction and differentiation of T Reg cells, and that has been extensively studied for several years [40] . In the tumor microenvironment, DC differentiation and function were suppressed by tumor-associated factors IL-10, VEGF, and TGFβ, resulting in immature/dysfunctional DC [6] . Dysfunctional DC directly contributed to the induction of IL-10-producing T Reg cells in vivo in human and in vitro [41, 42] . Tumorassociated plasmacytoid DC also induced IL-10 + T Reg generation [ Glucocorticoid-induced tumor necrosis factor (TNF) receptor family-related protein (GITR or DTA-1) is predominantly expressed on the surface of T Reg cells. An agonistic anti-GITR antibody administration in mice can abrogate T Reg -mediated immune suppression and enhance effective anti-tumor immunity in vivo [57, 58] . In addition, treatment with anti-GITR antibody in B16 mice elicited immune response and rejected tumor [59] . However GITR is not exclusively expressed on T Reg cell; it is also expressed by various CD4 + T cells and others. Therefore, the clinical therapeutic relevance of GITR blockade and its side effects on potential deficits of other effective immune cells remain to be determined.
Targeting Regulatory T Cells
OX40 (CD134) also belongs to TNF receptor family and expressed on activated T cells. Both naïve and activated T Reg express OX40. Similar to GITR, triggering OX40 by an agonistic antibody against OX40 reduces T Reg -mediated immune suppression and restores effector T-cell function both in vivo and in vitro [60] . It has been also shown that OX40 is necessary for T Reg development, homeostasis, and immunesuppressive activity. However, stimulation of OX40 signal in naïve T cells can abrogate T Reg -mediated suppression [61] .
Clinical relevance of the depletion of T Reg cells has been further confirmed by the treatment of cyclophosphamide (CY) in the patients bearing tumor. Cyclophosphamide is a nitrogen mustard alkylating agent that mediates DNA crosslinking. Low dose of CY administration improved patients' immune responses by reducing the number of T Reg cells and by decreasing the suppressive activity of T Reg cells [62] . Effects of T Reg depletion on anti-tumor immune responses were further investigated by the study on B16 melanomas mouse model [63] . Other immunosuppressants like cyclosporine A (CSA) and azathioprine might also inhibit T Reg cells generation [64, 65] . For instance, high dose of CSA abrogates T Reg cell generation; by contrast, low dose of CSA can promote T Reg cell development [64] . It is therefore important to determine whether lowdose of those agents can improve antitumor immunity in patients.
Targeting T Reg
Trafficking. Our group has demonstrated that human ovarian cancer cells and tumor-associated macrophage (TAM) produced chemokine CCL22, the ligand for CCR4 which functionally expressed on tumor T Reg cells, mediating T Reg cells trafficking to the tumor and ascites, and the blockade of CCL22 abrogated T Reg cells migration [4] . It has been demonstrated that chemokine receptor CCR4 is selectively expressed by T Reg cells, and the CCR4 and CCR4-associate chemokines axis is one of the most described tumor T Reg recruitment axes [66] . The administration of anti-CCR4 antibody effectively depletes CCR4 + T cells and inhibits T Reg cells migration in Hodgkin lymphoma [31] . Furthermore, the significant correlation between CCL17 or CCL22 chemokines and the number of tumor-infiltrating T Reg cells was found in patients with neoplastic meningitis and gastric cancer [30, 33] . CCL5 and CCL20 chemokines are also involved in T Reg trafficking, and that blockade of those chemokines reduces T Reg cells trafficking and inhibits tumor growth [34, 35] . We have shown that CXCL12/CXCR4 axis mediated T Reg trafficking to bone marrow [67] . Recently, a study has demonstrated that blockade of CXCR4 by a selective antagonist resulted in the significant reduction of intratumoral T Reg cells, which was associated with greatly increased antitumor immunity and an improved survival in an immunocompetent mouse model of ovarian cancer [68] .
Targeting TGFβ Signaling Pathway.
TGFβ is implicated in T Reg differentiation, conversion, and function. It is thought that blockade of TGFβ signaling pathway may alter T Reg phenotype and function and in turn enhances antitumor immunity [6] . In addition to T Reg cells, ovarian carcinoma cells can also produce TGFβ [69] . Notably, TGFβ is not only important for T Reg cell functional integrity, but also inhibits the proliferation and functional differentiation of T lymphocytes, NK cells, and macrophages [46, 70] . This may induce T-cell unresponsiveness to TCR stimulation, failure to produce Th1 cytokines, and production of additional TGFβ [46] . TGFβ signaling may also be crucial for tumor cell transformation. Therefore, targeting TGFβ signaling may be therapeutically meaningful. TGFβ inhibitor AP 12009 was tested in a Phase I/II clinical trial for advanced pancreatic cancer and other malignancies [71] . LY2109761, an inhibitor of TGFβ I/II receptors, can suppress pancreatic cancer metastases [72] . In a preclinical model, we have shown that anti-TGFβ can reduce T Reg cells in tumors and tumordraining lymph nodes. This effect is enhanced by B7-H1 blockade [73] . Nonetheless, it is clear that blocking TGFβ signaling may affect T Reg compartment. However, as TGFβ is implicated in multiple layers of biological activities, the ultimate clinical therapeutic efficiency and side effects of TGFβ signaling blockade remain to be investigated.
Targeting Inhibitory B7 Family Members.
The expression, regulation, functional, and clinical relevance of inhibitory B7 family members have been reviewed elsewhere [74] . Human ovarian cancer and cancer-associated myeloid antigen-presenting cells express high levels of B7-H1 (PD-L1), which are negatively associated with patient survival [74, 75] . Patients with high expression of B7-H1 had a significantly poor prognosis compared to the patients with low expression of B7H1 [76] . B7-H1 expression was also found inversely correlated to the intraepithelial CD8 + T lymphocyte count, indicating that B7-H1 on tumor cells may suppress antitumor CD8 + T cells [76] . The receptor, programmed death 1 (PD-1), is expressed on activated T-cell subsets, antigen-specific CD8 + T cells [77] , and T Reg [78] . Interestingly, B7-H1/PD-1 has been reported to be involved in the development of induced T Reg cells [79] . Therefore, targeting B7-H1/PD-1 signaling pathway may reduce T Reg development and function. As anti-PD-1 is in clinical application to treat patients with melanoma, renal cell carcinoma, and other cancers, further mechanistic studies on these patients will determine if the effects of anti-PD-1 on T Reg cells are mechanistically and clinically relevant.
In addition to B7-H1, human ovarian cancer and cancerassociated myeloid antigen-presenting cells also express high levels of B7-H4 (B7x, B7s1), which are negatively associated with patient survival [74, 80, 81] . Interestingly, T Reg cells can induce IL-10 expression by APCs and indirectly stimulate B7-H4 expression on APCs and convey suppressive activity to APCs [74, 80, 81] . Thus, it is tempting to speculate that blocking B7-H4 signaling pathway may disable the suppressive effects of T Reg cells on APCs. Notably, as the receptor for B7-H4 has not been identified, B7-H4 signaling is much less understood in both mouse and human system. Nonetheless, studies on ovarian cancer patients and preclinical cancer models suggest that interruption of B7-H4 signaling may lead to improved antitumor T-cell response and decreased T Reg suppressive function.
Conclusions
T Reg cells infiltrate tumor including ovarian cancer. Their phenotype, trafficking mechanism, suppressive activity, and clinical relevance have been defined in human cancer. However, recent evidence indicates that T Reg cells may not be stable and are subject to environmental regulation. In this regard, it remains poorly understood how T Reg cells evolve in human tumor microenvironment. Although their action mode of mechanisms has been investigated in many different physiological and pathological scenarios, the key suppressive mechanisms may be differed in different tumors or/and in different stages. Therefore, further patient-oriented studies are essential for dissecting T Reg cell biology. Nonetheless, targeting T Reg cells or/and reprogramming T Reg cells is an important strategy to treat patients with cancer. It is suggested that combinatorial therapy by incorporating T Reg manipulation may be ideal direction to develop novel therapeutic regimen to efficiently treat patients with cancer. 
